Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,998 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Anaplastic Large Cell Lymphoma, ALK-Positive, +86 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
View all 36 locations
View Trial Details
Active, not recruiting

Axi-cel in CNS Lymphoma

NCT04608487

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma

NCT04468841

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack (All Protocol Activities) Commack, New York, United States
View Trial Details
Active, not recruiting

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

NCT04790474

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Emek Medical Center Afula, Israel
  • Rambam Medical Center Haifa, Israel
  • Hadassah Ein-Kerem Medical Center Jerusalem, Israel
  • Shearei Zedek Medical Center Jerusalem, Israel
View Trial Details
Active, not recruiting

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

NCT04684108

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +20 more
Locations
  • The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui, China
  • Affiliated Beijing Chaoyang Hospital of Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Jishuitan Hostipal Beijing, Beijing Municipality, China
  • Shenzhen Second People's Hospital Shenzhen, Guangzhou, China
View all 14 locations
View Trial Details
Active, not recruiting

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

NCT02436707

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations
  • Arthur J.E. Child Comprehensive Cancer Centre Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • BCCA - Vancouver Vancouver, British Columbia, Canada
  • CancerCare Manitoba Winnipeg, Manitoba, Canada
View Trial Details

Related conditions